Aatru has developed and patented a unique and innovative negative pressure dressing. Upon FDA clearance, this refined design will be intended to serve the surgical incision market and the traditional NPWT market for chronic wounds. FDA submission is schedule for early Q2, 2020 - 510K Class II clearance.
Upon FDA approval, Aatru's patented technology is meant to deliver negative pressure solutions in dressings for multiple markets, from surgical sites to chronic wounds, to smart patch technology for cosmetic and dermal use. Future dressing designs include sensor technology and other therapies such as heat, light, electro-stimulation, etc.
Aatru Medical has built an extensive patent portfolio with over 40 global patent filings to date, a combination of granted and patent-pending. Aatru has filed Provisional, USPTO, and PCT to globally cover a wide range of designs, features, and embodiments.
Unlike the current industry-standard NPWT solutions in the market, the Aatru dressing, upon FDA approval, is intended to provide the patient with an exceptional wound dressing coupled with negative pressure in the therapeutic range without the need, discomfort, or the high cost of a mechanical pump.